Neuroendocrine brake for the treatment of morbid obesity. Preliminary report

Objectives: To demonstrate the preliminary results of a newtechnique named neuroendocrine brake, for surgical treatment ofmorbid obesity. Methods: In November 2003, three patientsunderwent the neuroendocrine brake operation performed by thelaparoscopic approach. The mean age was 46.4 years; all pati...

Full description

Bibliographic Details
Main Authors: Aureo Ludovico de Paula, Antônio Luiz de Vasconcelos Macedo, Alcyr Prudente, Luiz Silva, Vladimir Schraibman, Julio Gozani Neto, Jaques Pinus, Edson Kodor Cury, Paulo Szajnbok, Rodolfo Pio Di Dario, Luis Bertocco, Kelcen Diniz, Jarbas Gaudêncio, Luiz Gebin, Ulisses D’Orto, Daniel Císon, Felix Penhavel
Format: Article
Language:English
Published: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2005-06-01
Series:Einstein (São Paulo)
Subjects:
Online Access:http://www.einstein.br/revista/biblioteca/artigos/vol3/num_2/Vol3_N2_P110.pdf
Description
Summary:Objectives: To demonstrate the preliminary results of a newtechnique named neuroendocrine brake, for surgical treatment ofmorbid obesity. Methods: In November 2003, three patientsunderwent the neuroendocrine brake operation performed by thelaparoscopic approach. The mean age was 46.4 years; all patientswere female. Mean BMI was 42.3 kg/m2. The patients selectedpresented some relative or absolute contraindications to the useof gastrointestinal bypass techniques, including gastric ulcer anda family history of gastric malignancy(1) and chronic anemia (2).All patients had associated diseases, including type II diabetesmellitus (2), hypertension (2), obstructive sleep apnea (1),dyslipidemia (3), cholecystolithiasis (1), gastric ulcer (1) andchronic anemia (2). The laparoscopic technique consisted of anileal interposition at the proximal jejunum and longitudinalgastrectomy. Results: There was no conversion to open surgery orpostoperative complications. Sixteen months later, the meanpercentage of initial body weight loss was 44.6% and the meanBMI was 24.3 kg/m2. Glucose, triglyceride and cholesterol levelswere normalized, and sleep apnea showed remission. Conclusion:In spite of the reduced number of patients and short term followup, the good results suggest that the neuroendocrine brake maybecome an option for surgical treatment of morbid obesity in thenear future.
ISSN:1679-4508